Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Low-Dose Rivaroxaban, Cardiovascular Events, and Kidney Disease—Reply. Local targets link to admitted publications; unresolved targets remain external evidence.
Low-dose rivaroxaban and cardiovascular events in advanced kidney disease: the TRACK randomized clinical trial.
10.1001/jama.2026.9379 · 2026 · External reference
Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients.
10.1681/asn.2008080824 · 2009 · External reference
Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis.
10.7326/m19-0087 · 2019 · External reference
Oral anticoagulant initiation in patients with kidney failure on hemodialysis newly diagnosed with atrial fibrillation (2007-2020): an observational study of trends and disparities.
10.1016/j.xkme.2024.100926 · 2024 · External reference
Apixaban with antiplatelet therapy after acute coronary syndrome.
10.1056/nejmoa1105819 · 2011 · External reference
Dose-finding study of rivaroxaban in hemodialysis patients.
10.1053/j.ajkd.2015.01.022 · 2015 · External reference
